source
- Pfizer reports positive Phase 3 results for Elrexfio in relapsed multiple myelomaPfizer announced that its antibody-drug conjugate Elrexfio achieved a statistically significant and clinically meaningful improvement in progression-free survival for patients with relapsed or refr…
- FDA pilots real-time clinical trials as Amgen, AstraZeneca join proof-of-concept studies; AbbVie eyes KRAS biotech KestrelThe U.S. Food and Drug Administration announced a pilot program for "real-time" clinical trials, designed to cut the lag between data collection and regulatory review. AstraZeneca and Amgen have l…